Targeting indolent non-Hodgkin lymphoma.

about

Volatile metabonomic profiling in urine to detect novel biomarkers for B-cell non-Hodgkin's lymphoma.

P2860

Q55023339-65B14A60-4487-4CED-992F-A22D661F57A2

P2860

Targeting indolent non-Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q38917848

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Targeting indolent non-Hodgkin lymphoma.

@en

type

Item

label

Targeting indolent non-Hodgkin lymphoma.

@en

prefLabel

Targeting indolent non-Hodgkin lymphoma.

@en

P1476

Targeting indolent non-Hodgkin lymphoma.

@en

P2093

Alan P Skarbnik

http://www.w3.org/2001/XMLSchema#string

Andre H Goy

http://www.w3.org/2001/XMLSchema#string

Coleen Bejot

http://www.w3.org/2001/XMLSchema#string

Lori A Leslie

http://www.w3.org/2001/XMLSchema#string

Susan Stives

http://www.w3.org/2001/XMLSchema#string

Tatyana A Feldman

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis

Cancer statistics, 2016

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

P304

299-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1080/17474086.2017.1303374

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28277849

http://www.w3.org/2001/XMLSchema#string

Targeting indolent non-Hodgkin lymphoma.

about

P2860

P2860

Targeting indolent non-Hodgkin lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698